| 常用名 | 依那妥组单抗 | CAS号 | 1062149-33-0 |
|---|---|---|---|
| 价格 | ¥需询单/1g ¥需询单/5g | 纯度 | 98.0% |
| 备货期 | 需询单 | 库存 | 现货 |
| 产品详情(用途,包装等)
用途: Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo [1] [2]. 物理化学性质: CAS号:1062149-33-0 常用中文名:依那妥组单抗 常用英文名:Enavatuzumab 分子式: 分子量: 密度:N/A 沸点:N/A 熔点:N/A 闪点:N/A |